We are live on ! Find out more
VMI

VHCP Management II Portfolio holdings

AUM $379M
1-Year Est. Return 421.62%
This Fund
S&P 500
This Quarter Est. Return
+28.43%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$414M
AUM Growth
-$2.79M
Cap. Flow
-$71.4M
Cap. Flow %
-17.22%
Top 10 Hldgs %
87.78%
Holding
21
New
3
Increased
2
Reduced
8
Closed
4

Top Buys

Rank Stock Value
1
ECYT
Endocyte, Inc. Common Stock
ECYT
+$23.7M
2
VYNE icon
VYNE Therapeutics
VYNE
+$11.5M
3
GYRE icon
Gyre Therapeutics
GYRE
+$7.91M
4
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$7.09M
5
OBSV
ObsEva SA Ordinary Shares
OBSV
+$1.9M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$29.6M
2
ARGX icon
argenx
ARGX
+$22.9M
3
ZGNX
Zogenix, Inc.
ZGNX
+$19.5M
4
SVRA icon
Savara
SVRA
+$13.4M
5
ANAB icon
AnaptysBio
ANAB
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 93.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$128M 30.88%
1,035,657
– –
ECYT
2
DELISTED
Endocyte, Inc. Common Stock
ECYT
$39.1M 9.43%
+4,300,000
New +$23.7M
ASND icon
3
Ascendis Pharma A/S
ASND
$16.6B
$38.3M 9.25%
586,195
-526,819
-47% -$29.6M
BHVN
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$35.8M 8.64%
1,390,391
-328,214
-19% -$9.81M
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
$28.9M 6.98%
2,143,843
+155,000
+8% +$1.9M
ARGX icon
6
argenx
ARGX
$57.8B
$27.9M 6.73%
346,792
-302,873
-47% -$22.9M
ANAB icon
7
AnaptysBio
ANAB
$1.63B
$18.8M 4.54%
180,950
-101,600
-36% -$11.5M
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
$14.5M 3.5%
362,010
-492,047
-58% -$19.5M
GYRE icon
9
Gyre Therapeutics
GYRE
$670M
$14.3M 3.45%
73,817
+42,394
+135% +$7.91M
VYNE icon
10
VYNE Therapeutics
VYNE
$30.8M
$12.8M 3.08%
+4,722
New +$11.5M
BCRX icon
11
BioCryst Pharmaceuticals
BCRX
$2.38B
$10.6M 2.56%
2,220,971
-261,148
-11% -$1.34M
BLPH
12
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$8.63M 2.08%
276,625
– –
MNTA
13
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$7.71M 1.86%
+425,000
New +$7.09M
SPRO icon
14
Spero Therapeutics
SPRO
$67.2M
$6.92M 1.67%
485,615
– –
RARX
15
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$2.89M 0.7%
544,612
– –
SVRA icon
16
Savara
SVRA
$1.18B
$1.1M 0.27%
119,840
-1,139,660
-90% -$13.4M
AKTX
17
Akari Therapeutics
AKTX
$16.3M
– –
-533
Closed -$1.85M
LPCN icon
18
Lipocine
LPCN
$18.1M
– –
-22,760
Closed -$1.33M
PDSB icon
19
PDS Biotechnology
PDSB
$39.2M
– –
-48,755
Closed -$9.14M
ORKA
20
Oruka Therapeutics
ORKA
$5.55B
– –
-4,995
Closed -$1.46M

Similar funds

ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PI
PHH Investments Addison, Texas $378M AUM 19.74% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
WC
Whitnell & Co Oak Brook, Illinois $326M AUM 25.97% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return

VHCP Management II's Q1 2018 Portfolio in Review

As of Q1 2018, VHCP Management II held 21 positions worth $414M, down 0.67% from $417M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

VHCP Management II withdrew a net $71.4M in Q1 2018, closing 4 positions and reducing 8 holdings. Its most notable exit was PDS Biotechnology, an estimated $9.14M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier.

Against the trend, VHCP Management II opened a new position in Endocyte, Inc. Common Stock worth $39.1M.

  • VHCP Management II's largest Q1 2018 buy was Endocyte, Inc. Common Stock: 4,300,000 shares worth $39.1M.
  • VHCP Management II added most to Gyre Therapeutics in Q1 2018, an estimated $7.91M increase.
  • VHCP Management II's biggest Q1 2018 reduction was Ascendis Pharma A/S, cutting an estimated $29.6M.
  • VHCP Management II fully exited PDS Biotechnology in Q1 2018, selling an estimated $9.14M.
  • VHCP Management II's ten largest holdings make up 88% of its $414M portfolio in Q1 2018.
  • VHCP Management II opened 3 new positions and closed 4 in Q1 2018.
  • VHCP Management II's portfolio value fell 0.67% quarter-over-quarter to $414M.

Based on VHCP Management II's 13F filing for Q1 2018, filed 14 May 2018.